Phase I
This is the second IND to come out of the two companies’ collaboration. They will initiate a Phase I trial of the drug in cardiometabolic diseases.
The company says it plans to file an IND for the candidate, dubbed CFT8919, by the middle of next year.
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
This is after Larimar reported deaths in the highest dose levels of a nonhuman primate toxicology study.
Emergent said the vaccine candidate against the mosquito-borne illness showed an increase in immune response as measured by anti-chikungunya virus SNA.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
LION-101 is a novel recombinant AAV being developed as a one-time intravenous infusion for the treatment of adult and adolescent patients with Limb-Girdle Muscular Dystrophy Type 2I/R9.
The clinical trial, which will be conducted by Xilio, will assess XTX101’s safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 25, 2021.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
PRESS RELEASES